Upon announcing a significant collaboration for an upcoming clinical trial, shares of GeoVax Labs, Inc. (NASDAQ: GOVX) have surged notably. GOVX stock rose by 126.85% as of the most recent check of the current market, and it was trading at $4.55.
Collaboration In Phase 2b Clinical Trials
GeoVax (GOVX), a company that specializes in next-generation COVID-19 vaccines with two antigens, and Allucent, a leading worldwide clinical research company, have partnered to perform a Phase 2b clinical investigation for GEO-CM04S1. This statement is the follow-up to one made earlier in the year by GeoVax regarding an award obtained through the Rapid Response Partnership Vehicle (RRPV).
Information Regarding The Clinical Trial
As per the agreement, GeoVax is going to support a Phase 2b double-blind, randomized trial with 10,000 participants. The purpose of this research is to examine the relative effectiveness of GEO-CM04S1 vs an authorized or licensed COVID-19 vaccine in preventing PCR-confirmed SARS-CoV-2 infection that manifests symptoms.
Allucent, as part of BARDA’s Clinical Studies Network, will initiate and manage the BARDA-funded study. The combined financial support awarded to GeoVax and Allucent for this clinical evaluation amounts to approximately $367 million.
Advancing COVID-19 Vaccine Development
The support from BARDA’s Project NextGen is expected to significantly enhance the ongoing efforts to combat COVID-19 and its variants. GeoVax’s vaccine candidate, GEO-CM04S1, has been selected as a crucial component of these initiatives. Allucent, previously chosen by BARDA to be part of its Clinical Studies Network, expressed enthusiasm about executing the Phase 2b trial in collaboration with GeoVax.
Leveraging its clinical development expertise, Allucent aims to develop next-generation booster vaccines that will bolster global immunity and save lives. Project NextGen, a $5 billion initiative by HHS, seeks to advance a pipeline of innovative vaccines and therapeutics that offer broader and more durable protection against COVID-19 than the first-generation vaccines and medicines.
GeoVax’s candidate provides numerous features, including broader protection against variants of concern (VOC) and a longer duration of protection.
